Cosmo Announces SIX Ticker Symbol Change to “CMHC”

Ad hoc announcement pursuant to Art. 53 LR

Dublin, Ireland–(Newsfile Corp. – August 14, 2026) – Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that it will change its ticker symbol on the SIX Swiss Stock Exchange from “COPN” to “CMHC”. This change is expected to take effect at the opening of trading on Monday, August 17, 2026.

The new ticker symbol, “CMHC”, reflects the Company’s strategic focus on building health confidence. This is achieved by empowering patients, healthcare professionals, and partners with life-changing solutions that are developed at the intersection of science and technology. Cosmo’s goal is to drive innovation in life sciences by developing new therapies and technologies supported by AI, digital health and an entrepreneurial approach.

Giovanni Di Napoli, CEO, stated: “Today, Cosmo is a focused healthcare company built around three core strengths: innovation in gastroenterology, leadership in dermatology, and a growing digital and AI platform designed to be scaled up across MedTech and pharma. Our team is committed to building health confidence through execution, delivery and performance. This ambition will be reflected in our new ticker symbol.”

Existing shareholders do not need to take any action concerning the change to the ticker symbol. The Company’s stock will continue to be listed on the SIX Swiss Exchange and XETRA. The current XETRA ticker symbol (C43), ISIN (NL0011832936) and Valor number (32590356) will all remain unchanged.

About Cosmo

Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose – Building Health Confidence – our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit www.cosmohealthconfidence.com.

For further information, please contact:

investor.relations@cosmohc.com

Attachments

PDF – English

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309627

Staff

Recent Posts

Marpai Reports Second Quarter 2026 Financial Results

Successful turnaround leads to lower operating costs and improved gross margin; debt restructuring and subsequent…

6 hours ago

Health In Tech Reports Second Quarter 2026 Financial Results

Contracted Revenue of $32.3 Million as of June 30, 2026Pipeline Revenue of $66.3 Million as…

6 hours ago

Medicare Platform Secures $50 Million in Funds to Accelerate Its Mission for Senior Care

Credit facility mobilized by Nestpoint fuels Medicare Platform's rapid network growth — expanding AI enabled,…

6 hours ago

Collier County Commission Chairman Dan Kowal Endorses Michael Carbonara for Congress

The Army veteran and retired Collier County law enforcement officer backs Carbonara in Florida's 22nd…

6 hours ago

FBI Curaleaf Report Signals Federal Scrutiny Ahead for State Marijuana Operators Seeking DEA Registration

The FBI released 64 pages and withheld 147 more, most of them protected under grand…

6 hours ago

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information

Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDTNorthvale, New Jersey--(Newsfile Corp.…

9 hours ago